Clinical trials: Methylphenidate, completed
Normal Physiology
Dopaminergic Modulation of Brain Activation Using Simultaneous PET/Pharmacological MRI
Background: Dopamine (DA) is a chemical signal in the brain linked to learning, memory, and habits. Stimulant drugs like methylphenidate can increase DA in the brain. Researchers want to measure DA with and without this drug.
- Trial name
- NCT03326245
- Testing
- Methylphenidate Pill, Intravenous methylphenidate
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Attention-Deficit/Hyperactivity Disorder
Comparison of Lisdexamfetamine Dimesylate With Atomoxetine HCl in Attention-Deficit/Hyperactivity Disorder (ADHD) Subjects With an Inadequate Response to Methylphenidate
This study will evaluate how long it takes for ADHD symptoms to improve in subjects who are judged by the Investigator to have had an inadequate response to methylphenidate therapy.
- Trial name
- NCT01106430
- Testing
- Lisdexamfetamine Dimesylate, Atomoxetine Hydrochloride
- Where
- 64 sites in United States, Belgium and 8 more
- Volunteers
- 267 people
- Sponsor
- Shire
ADHD
Randomized, Double-blind Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents Aged 6-17
The main aim of this study is to see if giving LDX to children and adolescents aged 6-17 years with ADHD decreases symptoms of ADHD.
- Trial name
- NCT00763971
- Testing
- Lisdexamfetamine Dimesylate (LDX), Methylphenidate Hydrochloride
- Where
- 49 sites in Belgium, France and 8 more
- Volunteers
- 336 people
- Sponsor
- Shire
Attention-Deficit / Hyperactivity Disorder
A Long-Term Study on Safety of JNS001 in Adults With Attention-Deficit Hyperactivity Disorder
The main purpose of this study is to evaluate long-term safety and tolerability of JNS001 at 18 to 72 mg per day in adults with Attention-Deficit/Hyperactivity Disorder (ADHD).
- Trial name
- NCT01357993
- Testing
- JNS001
- Where
- 29 sites in Japan
- Volunteers
- 253 people
- Sponsor
- Janssen Pharmaceutical K.K.
Healthy
Study Examining Repeat Dosing of OROS® Methylphenidate (CONCERTA®) and Immediate Release Methylphenidate in Healthy Adults
There are two specific aims of this study. The first is to document the pharmacokinetics of dopamine transporter (DAT) receptor occupancy of repeated administration of orally administered, therapeutic doses of a short immediate…
- Trial name
- NCT00302393
- Testing
- OROS methylphenidate hydrochloride, methylphenidate hydrochloride
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Mood Disorder, Mental Disorder Diagnosed in Childhood
A Controlled Trial of Serotonin Reuptake Inhibitors Added to Stimulant Medication in Youth With Severe Mood Dysregulation
Severe mood dysregulation (SMD) is a very common syndrome in children. Its symptoms include very severe irritability, including persistent anger and frequent outbursts, as well as distractibility, hyperactivity, and other…
- Conditions
- Mood Disorder, Mental Disorder Diagnosed in Childhood, Attention Deficit and Disruptive Behavior Disorder, Attention Deficit Hyperactivity Disorder
- Trial name
- NCT00794040
- Testing
- Add-on citalopram following optimized methylphenidate
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- National Institute of Mental Health (NIMH)
Attention Deficit Hyperactivity Disorder
An Effectiveness and Safety Study Evaluating OROS Methylphenidate Hydrochloride (HCl), Ritalin (Methylphenidate HCl) and Placebo in Children With Attention Deficit Hyperactivity Disorder
The purpose of this study is to provide data on the effectiveness of the OROS Methylphenidate Hydrochloride (HCl) formulation compared to placebo and standard immediate-release Ritalin with respect to improving attention and…
- Trial name
- NCT00269776
- Testing
- OROS (methylphenidate HCl), Ritalin (methylphenidate)
- Sponsor
- Alza Corporation, DE, USA
Fatigue in Multiple Sclerosis
Testing the Effects of Methylphenidate on Multiple Sclerosis
Up to 95% of individuals with Multiple Sclerosis report experiencing cognitive fatigue, characterized by a lack of energy, feelings of exhaustion, an the perception that one is unable to partake in daily activities.
- Trial name
- NCT02286557
- Testing
- Methelphenidate
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Kessler Foundation
Drug Abuse
The Effects of Expectation on Natural and Drug -Induced Rewards
Background: Environmental cues frequently induce expectancies in individuals that may strongly influence the actual experience associated with the cue.
- Trial name
- NCT01036230
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- National Institute on Drug Abuse (NIDA)
Attention Deficit Hyperactivity Disorder
Mindfulness-Based ADHD Treatment for Children: a Feasibility Study
Attention-Deficit/Hyperactivity Disorder (ADHD) affects 11% of children and leads to adverse outcomes. Medications, while often effective in reducing certain ADHD symptoms, have many disadvantages, including misuse and side…
- Trial name
- MBAT-C (NCT04737512)
- Testing
- Mindfulness-Based ADHD Treatment for Children, Goal-Standard Medication (Treatment as Usual)
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Yale University
Pain
Neural Correlates of Acute Pain Dynamics
This work aims to study the neural correlates and determinants of pain dynamics related to changes in a noxious stimulus.
- Trial name
- NCT05669924
- Testing
- Methylphenidate
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Northwestern University
Healthy Volunteers
A Double-blind Randomized, Placebo-controlled, Crossover Study of Single Doses of OROS Methylphenidate Hydrochloride (CONCERTA) and Long-acting Methylphenidate Hydrochloride (RITALIN LA) in Healthy Adults
This is a double-blind, placebo-controlled study, three-period crossover study to examine the likeability of a single dose of OROS MPH (CONCERTAÒ 90mg) and a single dose of Long-acting MPH (RITALIN LAÒ 90mg).
- Trial name
- NCT00302354
- Testing
- OROS methylphenidate HCl, SODAS methylphenidate HCl
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Traumatic Brain Injury, TBI
Methylphenidate for Attention Problems After Pediatric TBI
Traumatic Brain Injury (TBI) - methylphenidate treatment
- Conditions
- Traumatic Brain Injury, TBI, ADHD
- Trial name
- NCT01933217
- Testing
- Methylphenidate
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Attention-deficit/Hyperactivity Disorder
Examining Tolerance to CNS Stimulants in ADHD
Although stimulant medication is a well-established treatment for ADHD, it is often necessary for doctors to increase the dose over time to maintain the benefits of the medication.
- Trial name
- NCT02039908
- Testing
- Methylphenidate
- Where
- United States
- Volunteers
- 267 people
- Sponsor
- Florida International University
ADHD
The Relationship Between CES1 Genotype and Methylphenidate Response in Children With ADHD - INDICES Work Package 6
This is a prospective observational study of a cohort of children diagnosed with Attention Deficit Hyperactive Disorder (ADHD) and followed with weekly assessments during the first 12 weeks of Methylphenidate (MPH) treatment, and…
- Trial name
- NCT04366609
- Testing
- Methylphenidate
- Volunteers
- 207 people
- Sponsor
- Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital
Attention Deficit Hyperactivity Disorder, ADHD
Imaging Stimulant and Non Stimulant Treatments for ADHD: A Network Based Approach
The growing number of medications used to treat attention-deficit/hyperactivity disorder (ADHD) raises important questions about whether different medications have similar or different therapeutic mechanisms of action.
- Trial name
- NCT01678209
- Testing
- fMRI scans, Atomoxetine arm, Methylphenidate arm
- Where
- United States
- Volunteers
- 127 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
Attention Deficit Hyperactivity Disorder
Should Chronic Stimulant Medications be Continued Preoperatively in Patients With Attention Deficit Hyperactivity Disorder(ADHD)
Patients on chronic stimulant therapy for the treatment of Attention deficit hyperactivity disorder (ADHD) who are undergoing an outpatient surgical or diagnostic procedure will be randomized to one of two groups: stimulant…
- Trial name
- NCT01740206
- Testing
- Amphetamine and/or methylphenidate, Hold stimulant medication
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Nationwide Children's Hospital
Attention Deficit Hyperactivity Disorder
Naturalistic Substitution of Concerta in Adult Subject With ADHD Receiving Immediate Release Methylphenidate
This is a single-blind study looking at the efficacy and satisfaction of Concerta substitution in adult subjects with ADHD receiving immediate release methylphenidate.
- Trial name
- NCT00302406
- Testing
- methylphenidate hydrochloride, OROS methylphenidate hydrochloride (CONCERTA)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Massachusetts General Hospital
Attention Deficit Hyperactivity Disorder
A Multicenter Study Comparing the Efficacy and Safety of OROS Methylphenidate HCl, Ritalin (Methylphenidate HCl) and Placebo in Children With Attention Deficit Hyperactivity Disorder
The purpose of this study is to evaluate the efficacy and safety of OROS® Methylphenidate HCl as compared with placebo and standard immediate-release Ritalin® (taken three time per day) for the treatment of Attention Deficit…
- Trial name
- NCT00269802
- Testing
- OROS methylphenidate HCl, Ritalin
- Sponsor
- Alza Corporation, DE, USA
Psilocybin
Precision Functional Brain Mapping in Psilocybin
This project will employ functional brain imaging to study the mechanism and immediate and long-term effects of psilocybin, a serotonin receptor 2A agonist, on cortical and cortico-subcortical brain networks in healthy adults.
- Trial name
- Psilocybin PFM (NCT04501653)
- Testing
- Psilocybin, Methylphenidate
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine